Free shipping on all orders over $ 500

Onvansertib

Cat. No. M13718

All AbMole products are for research use only, cannot be used for human consumption.

Onvansertib Structure
Synonym:

PCM-075; NMS-1286937; NMS-P937

Size Price Availability Quantity
5mg USD 70  USD70 In stock
10mg USD 105  USD105 In stock
25mg USD 175  USD175 In stock
50mg USD 270  USD270 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?
Quality Control & Documentation
Biological Activity

Onvansertib (PCM-075, NMS-1286937, NMS-P937) is a first-in-class, third-generation, oral, highly selective PLK1 inhibitor that induces tumor cell arrest in the G2/M phase and triggers apoptosis. It has a median IC50=136nM against a variety of CRC cell lines and inhibits xenograft models such as HT-29, HCT-116, and Colo-205 well.

Chemical Information
Molecular Weight 532.52
Formula C24H27F3N8O3
CAS Number 1034616-18-6
Solubility (25°C) DMSO 21 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Roberta Affatato, et al. Ther Adv Med Oncol. Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas

[2] Anais Hagege, et al. Theranostics. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy

[3] Christopher A Raab, et al. Biochim Biophys Acta Rev Cancer. Non-mitotic functions of polo-like kinases in cancer cells

[4] Amer M Zeidan, et al. Clin Cancer Res. A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

[5] Xiaolong Wang, et al. Eur J Pharmacol. Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by α 1-blockers

Related PLK Products
(1E)-CFI-400437 dihydrochloride 

(1E)-CFI-400437 dihydrochloride is a potent PLK4 (IC50= 0.6 nM) inhibitor and selective against other members of the PLK family (>10 μM).
3MB-PP1

3MB-PP1 is a bulky purine analog and inhibitor of Polo-like kinase 1 (Plk1) that blocks mitotic progression and cytokinesis by targeting Plk1 in cells expressing the analog-sensitive Plk1 allele. 3MB-PP1 also specifically inhibits the activity of Leu93 mutant Zipper-interacting Ssn3 (Cdk8). 3MB-PP1 inhibits the activity of Leu93 mutant Zipper-interacting Ssn3 (Cdk8). In addition, 3MB-PP1 specifically inhibits the activity of analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits the Leu93 mutant Zipper-interacting protein kinase (Leu93-ZIPK; IC50=2 μM). 3MB-PP1 can be used in the mycelium of Candida albicans. 3MB-PP1 can be used in studies related to mycelium formation and cell division in Candida albicans.
CYC-800

CYC-800 is a PLK1 inhibitor that can be used in tumor-related studies.
SOL-686

SOL-686 is a PLK1 inhibitor that can be used in glioma-related studies.
BAL0891

BAL0891 is a potential first-in-class PLK1/TTK inhibitor with antiproliferative activity for studies related to solid tumors.
  Catalog
Abmole Inhibitor Catalog




Keywords: Onvansertib, PCM-075; NMS-1286937; NMS-P937 supplier, PLK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.


 
Get to Know Us
Customer Support
Resources
Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.